Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

  • 7 May 2018 4:43 PM | Hawk Tran (Administrator)

    FY18 MSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Applications submitted to the FY18 MSRP must address at least one of the following Focus Areas:

    1) Obstacles to Remyelination and/or Obstacles to Axonal Protection in MS

    • Examples of acceptable studies include, but are not limited to, the roles of inhibitory factors, trophic factors, cell-cell interactions, and cell intrinsic factors.
    • Utilization and/or development of models that reflect the disease progression and translational approaches to evaluate benefit are encouraged.

    Note: Projects addressing the basic mechanisms of demyelination and neurodegeneration, inflammation or prevention of secondary injury following inflammation will not be considered for funding.

    (2) Correlates of Disease Activity and Progression in MS

    Studies may identify or validate correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

    • Correlates include clinical outcome measures, patient self-reported measures, and imaging and non-imaging biomarkers.
    • Examples of acceptable cohorts for study include controlled clinical trials, observational studies, and registries. Analyses may utilize existing clinical data and outcome measures, specimens, and/or imaging data.

    Note: The study must leverage pre-existing specimens and/or data that are available at the time of application submission; collection of additional data on the existing cohort is allowed.

    (3) Biology and Measurements of MS Symptoms (Exploration – Hypothesis Development Award ONLY!)

    • Symptoms may include pain, fatigue, cognitive dysfunction, visual impairment, motor impairment, impaired mobility, loss of bladder control, sexual dysfunction, depression, and anxiety.
    • Examples of acceptable studies include, but are not limited to, the following: development of measurements for future interventional studies to alleviate symptoms, rehabilitation, mechanisms underlying symptoms of MS, development and/or validation of outcome measures and tools for symptoms, and observational studies on the prevalence or significance of symptoms.

    Note: Studies of disease-modifying or regenerative therapies that secondarily impact symptoms will not be considered for funding.

    http://cdmrp.army.mil/funding/msrp

    Exploration - Hypothesis Development Award – Preproposal due June 26, 2018

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    • Pre-application submission is required; application submission is by invitation only.
    • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.
    • Preliminary data and/or published data not required.
    • Anticipated that budgets will not exceed $150,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 2 years
    • Clinical trials not allowed.

    Investigator-Initiated Research Award – Preproposal due June 26, 2018

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    • Pre-application submission is required; application submission is by invitation only.
    • Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.
    • Preliminary and/or published data required.
    • Anticipated that budgets will not exceed $600,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 3 years
    • Clinical trials not allowed.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism is also found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682/5507
    help@eBrap.org


  • 7 May 2018 2:22 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support the United States Medical Research Acquisition Activity.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018 Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    http://cdmrp.army.mil/pubs/press/2018/18kcrppreann

    Concept Award

    Investigators at all academic levels.

    ·      Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

    ·      Emphasis on innovation.

    ·      Funding for clinical trials is not allowed.

    ·      Preliminary data are not allowed.

    ·      Blinded review

    ·     Maximum funding of $75,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 1 year.

    Idea Development Award

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

    Early Career Investigators:

    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

    ·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

    ·      Preliminary data are required.

    ·      Innovation and Impact are the most important review criteria.

    ·      Funding for clinical trials is not allowed.

    ·      FY18 KCRP Areas of Emphasis are strongly encouraged.

    ·      Maximum funding of $400,000 in direct costs (plus indirect costs).

    ·      Period of performance is not to exceed 2 years.

    Physicians Research Award

    The PI must be a physician with clinical duties and/or responsibilities who, at the application submission deadline, is within 3 years of having initiated his/her first appointment as an Instructor, Assistant Professor, or equivalent

    ·      Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research.

    ·      This award emphasizes equally the quality of the proposed research project and the career development of the Principal Investigator (PI), which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.

    ·      Emphasis on multi-institutional/multi-disciplinary and collaboration.

    ·      Preliminary data are not required.

    ·      Funding for clinical trials is not allowed

    ·      Maximum funding of $200,000 in direct costs (plus indirect costs).

    ·      Period of performance is not to exceed 2 years.

    Technology Development Award

    Independent investigators at or above the level of Assistant Professor (or equivalent).

    ·      Supports emerging technologies to aid clinical and patient outcomes.

    ·      Preliminary data are required (need not be in kidney cancer).

    ·      Funding for clinical trials is not allowed.

    ·      Maximum funding of $300,000 in direct costs (plus indirect costs).

    ·      Period of performance is not to exceed 3 years.

    Translational Research Partnership

    Investigators at or above the level of Assistant Professor (or equivalent).

    ·      Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

    ·      Supports translational correlative studies.

    ·      Preliminary data are required.

    ·      Funding for clinical trials is not allowed.

    ·      Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 4 May 2018 10:01 AM | Hawk Tran (Administrator)

    FY18 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

     

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The following mechanisms have been released:

    http://cdmrp.army.mil/funding/gwirp

     

    Clinical Trial Award – Preproposal due July 13, 2018

    • Independent investigators at all academic levels
    • Submission of a pre-application is required: application submission is by invitation only.
    • Supports rapid implementation of clinical trials with the potential to have a significant impact on GWI.
    • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
    • Early phase or pilot clinical trials (Phase 0, I, or I/II) do not require preliminary data. Larger, more definitive clinical trials, including expansion of promising pilot trials, must include preliminary data to include safety in a GWI Veteran population.

    Biorepository Contribution Option:

    • Supports additional costs associated with submission of samples and data to the GWIRP supported Biorepository Resource Network.
    • Applicants must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP-supported Biorepository Resource Network.
    • Application to this option is not a requirement for Clinical Trial Award submission.
    • Maximum funding of $825,000 for direct costs (plus indirect costs).
    • Maximum funding of $841,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).
    • Maximum period of performance is years

     

    Qualitative Research Award – Preproposal due July 13, 2018

    • Independent investigators at all academic levels
    • Submission of a pre-application is required; application submission is by invitation only.
    • Supports qualitative research studies that seek to understand the experiences, perceptions, barriers, and beliefs of Veterans suffering from GWI and those responsible for their care.
    • Research outcomes should ultimately be translated into educational materials and tools to better inform Veterans and their caregivers of healthcare providers about GWI and its care.
    • Clinical trials are not allowed.
    • Maximum funding is $400,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

     

    Investigator-Initiated Focused Research Award – Preproposal due July 13, 2018

    • Independent investigators at all academic levels
    • Submission of a pre-application is required; application submission is by invitation only.
    • Supports research from idea generation through preclinical validation under two tiers:
      • Discovery Tier:  Supports basic research and proof-of-concept research; preliminary data are not required.
      • Applied Research Tier:  Supports advanced development of more mature therapeutic or diagnostic research. Projects may range from target or marker validation to data collection for FDA submission.  Preliminary data from the field of GWI are required.
    • Clinical trials are not allowed.

    Biorepository Contribution Option:

    ·         Supports additional costs associated with submission of samples and data to the GWIRP-supported Biorepository Resource Network.

    ·         Applicants must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP-supported Biorepository Resource Network.

    ·         Application to this option is not a requirement for Clinical Trial Award submission.

    • Maximum direct costs and period of performance vary based on Tier:
      • Discovery Tier:  Maximum funding of $230,000 or $246,000 with the Biorepository Contribution Option for direct costs (plus indirect costs) for a maximum of 2 years.
      • Applied Research Tier:  Maximum funding of $700,000 or $716,000 with the Biorepository Contribution Option for direct costs (plus indirect costs) for a maximum of 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 4 May 2018 10:00 AM | Hawk Tran (Administrator)

    FY18 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY18 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted.

    • Adrenal Cancers
    • Bladder Cancer
    • Blood Cancers
    • Brain Cancer
    • Cancer in children, adolescents, and young adults*
    • Colorectal cancer
    • Immunotherapy+
    • Listeria-based reginmens for cancer
    • Liver cancer
    • Lymphoma
    • Melanoma and other skin cancers
    • Mesothelioma
    • Myeloma
    • Neuroblastoma
    • Pancreatic cancer
    • Pediatric brain tumors
    • Stomach cancer

    *The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between the ages of 15-39 years.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s)

    As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

    The FY18 PRCRP Military Relevance Focus Areas are listed below:

    To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY18 PRCRP seeks to support studies that are responsive to at least one of Military Relevance Focus Areas listed below:

    • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
    • Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, and their beneficiaries and the general public

    http://cdmrp.army.mil/funding/prcrp

     

    Career Development Award – Letter of Intent August 28, 2018

    Principal Investigator (PI): Independent early-career investigator within 10 years of completing terminal degree (excluding time spent in medical residency or on family medical leave) at the time of the application submission: time spent as a postdoctoral fellow is not excluded.

    Postdoctoral fellows are not eligible.

    Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research 

    The PI and the Career Guide do not need to be located at the same organization.

    ·         Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.

    ·         Must address at least one of the FY18 PRCRP Topic Areas.

    ·         Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are not required.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $360,000 in direct costs (plus indirect costs)

    ·       Maximum period of performance is 3 years

     

    Idea Award with Special Focus – Preproposal due June 20, 2018

    Independent investigator with a faculty-level appointment (or equivalent)

    Only one pre-application per PI is allowed.

    ·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, Veterans, other military beneficiaries, and the American Public.

    ·         Emphasis on innovation and military relevance/impact.

    ·         Must address at least one of the FY18 PRCRP Topic Areas.

    ·         Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.

    ·         Inclusion of preliminary data discouraged.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $400,000 in direct costs (plus indirect costs)

    ·       Maximum period of performance is 2 years

     

    Translational Team Science Award – Preproposal due June 20, 2018

    At least two and up to three PIs must partner in one overarching correlative or translational research study in at least one  of the required FY18 PRCRP Topic Areas.

    The PIs must be at or above the level of Assistant Professor or equivalent.

    At least one military/Department of Veterans Affairs investigator is encouraged to be included as an equal partner.

    ·         Supports hypothesis-driven translational studies associated with an ongoing or completed clinical trial and are focused on research for the next-phase clinical research.

    ·         Must address at least one of the FY18 PRCRP Topic Areas.

    ·         Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.

    ·         Encourages research in quality of life, longitudinal cancer risk studies, and risk straficiation for primary and metastatic disease.

    ·         Preliminary data are required.

    ·         Clinical trials are allowed.

    ·       Maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)

    ·       Maximum period of performance is 4 years

     

    Impact Award – Preproposal due June 20, 2018

    Independent investigators at or above the level of Assistant Professor (or equivalent).

    Only one pre-application per Principal Investigators (PI) is allowed.

    • Supports hypothesis –driven high-impact research.
    • Encourages application that support the ideas that specifically focus on critical scientific and clinical cancer issued.
    • Emphasis on impact, transformation, and continuity of research.
    • Must address at least one of the FY18 PRCRP Topic Areas.
    • Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.
    • Preliminary data are required.
    • Clinical trials are allowed.
    • Maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)
    • Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 4 May 2018 10:00 AM | Hawk Tran (Administrator)

    FY18 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    Applications submitted to the FY18 LCRP must address at least one of the eight Areas of Emphasis listed below:

     

    • Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.

    ·         Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.

    ·         Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.

    ·         Identify innovative strategies for prevention and treatment of lung cancer.

    ·         Understand predictive markers to identify responders and nonresponders.

    ·         Understand mechanisms of resistance to treatment (primary and secondary).

    ·         Understand contributors to lung cancer development other than tobacco.

    ·         Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

    http://cdmrp.army.mil/funding/lcrp

    Concept Award – Letter of Intent due July 26, 2018

    ·         All investigators at or above the level of postdoctoral fellow (or equivalent)

    ·         Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer

    • Emphasis on innovation
    • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or be eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
    • Clinical trials not allowed

    ·         Preliminary data discouraged (not consistent with intent of award mechanism)

    ·         Military relevance strongly encouraged

    • Maximum funding of $100,000 in direct costs (plus indirect costs)

    ·         Period of performance should not exceed 1 year

     

    Career Development Award – Letter of Intent due September 6, 2018

    ·         Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

    ·         Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.

    ·         Must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one of more federally or privately funded, non-mentored, peer-reviewed grants

    ·         Mentor:  At or above the level of Associate Professor (or equivalent);

    ·         Must have a  strong publication and funding record in lung cancer research

    ·         Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher

    ·         Clinical trials not allowed

    ·         Preliminary data not required

    ·         Military relevance strongly encouraged

    ·         Maximum funding of $250,000 in direct costs (plus indirect costs)

    ·         Period of performance should not exceed 2 years

     

    Idea Development Award – Preproposal due June 26, 2018

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
    • New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    o   Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award

    o   Be within 10 years of first faculty appointment (or equivalent)

    • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research
    • Emphasis on innovation and impact
    • New Investigators: Supports applicants early in their faculty appointments or in the process of developing independent research careers
    • Clinical trials not allowed
    • Preliminary data required, but may be from outside of lung cancer

    ·         Military relevance strongly encouraged

    ·         Maximum funding of $350,000 in direct costs (plus indirect costs)

    ·         Period of performance should not exceed 2 years

     

    Investigator-Initiated Translational Research Award – Preproposal due June 26, 2018

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations
    • Intended to fund a broad range of translational studies.
    • Clinical trials not allowed.
    • Preliminary Date required, but may be from outside of lung cancer.
    • Military relevance strongly encouraged.

    ·         Maximum funding of $400,000 in direct costs (plus indirect costs)

    • Period of performance should not exceed 2 years

     

    Translational Research Partnership Award – Preproposal due June 26, 2018

    • Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications
    • One partner is strongly encouraged to be from a Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center or research laboratory.
    • Non-Traditional Partnerships are encouraged.
    • Clinical trials are allowed.
    • Preliminary data required, but may be from outside of lung cancer
    • Maximum combined funding of $900,000 in direct costs (plus indirect costs)
    • Maximum period of performance is 3 years
    • Military relevance strongly encouraged

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 1 May 2018 2:46 PM | Hawk Tran (Administrator)

    FY18 BMFRP Program Announcement and General Application Instructions for the following award mechanism are posted on Grants.gov.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/funding/bmfrp

    Idea Development Award – Preproposal due July 16, 2018

    Established Investigators:
    Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree
    or
    Early-Career Investigators:
    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or on family medical leave) at the time of application submission deadline are eligible.

    • Preapplication is required; application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (BMF).
    • Strong BMF research team.
    • May include relevant preliminary data.
    • Maximum funding of $325,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 2 years
    • Clinical trials will not be supported.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov website. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov website. For email notification when the Program Announcement is released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBRap.org


  • 27 Apr 2018 8:23 AM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Vision Research Program (VRP) to support innovative, high-impact vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The VRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 VRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in July 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    http://cdmrp.army.mil/pubs/press/2018/18vrppreann

    Focused Translational Team Science Award (FTTSA)

    PIs must be independent investigators at or above the level of Associate Professor (or equivalent) with experience in developing and running large-scale initiatives.

    • Co-investigators may be independent investigators at all academic levels (or equivalent).
    • Preproposal is required; application submission is by invitation only.
    • Support highly collaborative and translational team initiatives that would fundamentally advance the understanding and treatment of vision trauma. 
    • Must focus on eye injury or visual dysfunction as related to a traumatic event.  Examples of trauma include, but are not limited to:
    • Blast, blunt, thermal or chemical trauma;
    • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
    • Ionizing radiation
    • Must be a multifaceted, multidisciplinary and highly coherent investigation with 3-5 teams addressing complementary and synergistic questions that center around a specific trauma.  Examples of questions include, but are not limited to:
    • Elucidation of molecular, cellular, and biophysical mechanisms;
    • Identification of biomarkers and potential therapeutic targets;
    • Development and validation of therapeutic agents and/or devices;
    • Development and validation of drug delivery platforms appropriate for said trauma;
    • Development or improvement of clinically relevant models for said trauma;
    • Design of protection to mitigate the impact of said trauma on eye and vision.
    • The proposal should spell out the goals of individual teams as well as describe the ways for the teams to cooperate and effectively share and utilize the newly acquired knowledge in moving the project forward.
    • Preliminary data required.
    • Clinical trials are not allowed
    • Will be funded by Cooperative Agreement.
    • Emphasis is on synergy, translational potential, and strategy to transition findings into products.
    • Maximum funding of $5,000,000 for direct costs (plus indirect costs)
    • Maximum period of performance is year

    Investigator Initiated Research Award (IIRA)

    • Independent investigators at all academic levels (or equivalent).
    • Preproposal is required; application submission is by invitation only.
    • Must focus on eye injury or visual dysfunction as related to a traumatic event.  Examples of trauma include, but are not limited to:
      • Blast, blunt, thermal or chemical trauma;
      • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
      • Ionizing radiation
    • Preliminary data required.
    • Clinical trials are not allowed.
    • Emphasis is on impact and innovation.
    • Maximum funding of $500K for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Expansion Award (EA)

    • Current Principal Investigator (PI) of VRP awards that were initiated in FY13, FY14, or FY15
    • Each PI is eligible to submit one application per previous award received.
    • Preproposal is required; both preproposal submission and full application submission are by invitation only.
    • Support the continued investigation and further development of highly impactful VRP-funded projects that were initiated in FY13, FY14, or FY15.
    • Applications must include an Outcomes Statement that briefly details the research funded through the initial VRP award and describes the results, accomplishments, and outcomes from that award.  PIs should explain how these results, accomplishments, and outcomes relate to the proposed research and describe how expansion of the original research results would impact vision research and patient care.
    • Preliminary data required.
    • May support preclinical studies that involve cell lines and/or animal models, clinical studies involving human subjects and/or human anatomical substances, or pilot clinical trials that collect preliminary data to support the rationale and design of subsequent clinical trials.
    • Emphasis is on translational potential and impact.
    • Maximum funding of $500K for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Apr 2018 3:07 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $30 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP) to support innovative, high-impact spinal cord injury research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The SCIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    For FY18, SCIRP encourages applications that address the critical needs of SCI research and patient care in one or more of the following FY18 Focus Areas:

    • Neuroprotection
    • Biomarkers
    • Bladder and bowel dysfunction and neuropathic pain
    • Psychosocial issues relevant to SCI in  individuals with SCI and their caregivers
    • Rehabilitation and regeneration

    http://cdmrp.army.mil/pubs/press/2018/18scirppreann

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.
    • Preclinical data required for all clinical trial applications.
    • Maximum funding of $3M for direct costs (plus indirect costs)
    • Maximum period of performance is years

    Investigator-Initiated Research Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.
    • Preliminary data required.
    • Clinical trials not allowed.
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years.

    Qualitative Research Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund qualitative research on military Service members and Veterans in the years following SCI.
    • Qualitative research is defined as a form of social inquiry that focuses on understanding the way that people interpret and make sense of their experiences and the world in which they live (i.e., seek to understand the human experience).
    • Preliminary data encouraged, but not required.
    • Clinical trials not allowed.
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Translational Research Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.
    • Preliminary data required
    • The SCIRP TRA may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
    • Maximum funding of $1.25M for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Apr 2018 9:17 AM | Hawk Tran (Administrator)

    FY18 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The mission of the ALSRP is to fund innovative pre-clinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

    http://cdmrp.army.mil/funding/alsrp

    The following mechanisms are planned for release:

    Therapeutic Development Award – Preproposal due June 22, 2018

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only
    • Supports post-discovery, preclinical development of therapeutics for ALS
    • Preliminary data, including identify and purity of an identified bioactive compound(s), are required
    • Types of efforts that will be supported include:
      • Confirmation of candidate therapeutics obtained from screening or by other means
      • Validation of early pilot studies in multiple model systems and/or replicating preliminary data with more time points or additional doses
      • Optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices
      • Investigational New Drug (IND)-enabling studies
    • Clinical trials are not allowed
    • Collaboration with industry is encouraged
    • Does not support screening or development of screens or models
    • New! The following option, with additional funding for qualified applications, is being offered:
    • Therapeutic Relevance Option supports development of markers that will improve the drug development process in parallel with the main therapeutic advancement effort.
    • Applicants must submit a Therapeutic Relevance Statement that clearly describes how the marker is quantifiable and has potential to improve the efficacy of the therapy development process.
    • Application to this option is not a requirement for TDA submission
    • A TDA application requesting the higher level of funding that does not meet the specified criteria may be funded at the lower level
    • Standard award maximum funding of $1,000,000 for direct costs
    • Standard award with Option:
      • If applying for the Therapeutic Relevance Option, maximum funding of up to $1,250,000 for direct costs
    • Maximum period of performance is 2 years
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

     

    Therapeutic Idea Award – Preproposal due June 22, 2018

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only.
    • Supports new ideas aimed at drug or treatment discovery that are still in the early stages of development
    • Preliminary data are not required
    • Types of efforts that will be supported include:

    o    Exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality

    o    Development, modification, and use of high-throughput screens and novel model systems to define or assess lead compounds

    o    Projects that focus primarily on investigating the pathophysiology of ALS are outside of the scope of this announcement

    • Maximum funding of $500,000 for direct costs
    • Maximum period of performance is 2 years
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 5 Apr 2018 2:29 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriations Act provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Focus Areas:  The goal of the FY18 TSCRP is to fund exploratory, pioneering and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY18 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY18 Focus Areas:

    ·        Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency

    ·        Improving TSC disease models

    ·        Examining the clinical aspects of TSC, including phenotypic heterogeneity

    ·        Facilitating therapeutics, biomarkers, and clinical trials research

    http://cdmrp.army.mil/pubs/press/2018/18tscrppreann

    Exploration - Hypothesis Development Award

    • Investigators at all academic levels (or equivalent), including postdoctoral fellows
    • Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.
    • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
    • Preliminary data are not required.
    • Research projects must be innovative, feasible, and supported by a strong rationale.
    • Clinical trials are not allowed.
    • Maximum funding of $100,000 for direct costs (plus indirect costs)
    • Maximum period of performance is year

    Idea Development Award

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);
    • or
    • New Investigators:  
    • Independent investigator at or below the level of Assistant Professor (or equivalent); or
    • Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC thereby bringing his/her expertise to the field.
    • Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a PI of one or more Federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K/R00 Awardees are eligible to apply.)
    • Must not have received a New Investigator Award previously from any program within the CDMRP.
    • Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.
    • Preliminary data are expected.
    • Clinical trials are not allowed.
    • New Investigator Option supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in TSC research.
    • Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed separately.
    • Maximum funding of $450,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Clinical Translational Research Award

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Supports forward or reverse clinical/translational research studies.
    • Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 
    • Preclinical studies may be appropriate but must include a clinical component.
    • Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
    • Preliminary data are required
    • Maximum funding of $600,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software